NCT00431873 - A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Lymphocytic Leukemia, Chronic

Interventions

DRUG

MGCD0103

MGCD0103 Administered orally three times per week.

Trial Locations (13)

Ohio State University, James Cancer Hospital, Colombus

Cleveland Clinic/Chronic Leukemia/Multiple Myeloma Program, Cleveland

Gabrail Cancer Center, Canton

Veteran Affairs Medical Center Research Service, Kansas City

MD Anderson Cancer Center, Houston

Memorial Sloan-Kettering Cancer Center, New York

Queen Elizabeth II Health Sciences Centre, Halifax

McMaster University Health Center, Hamilton

Ottawa Hospital - General Campus, Ottawa

UHN - Princess Margaret Hospital, Toronto

Hopital Charles-LeMoyne, Greenfield Park

Hopital Maisonneuve-Rosemont, Montreal

CHA, Hopital Enfant-Jesus, Québec